Search
LEARN MORE ABOUT OUR FEARLESS PURSUIT
NEW YORK , Oct. 21, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the combination of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, and
GET INVESTOR INFORMATION
HEAR OUR STORY
READ OUR PUBLICATIONS
EXPLORE OUR PIPELINE
JOIN OUR TEAM
